Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children
Overview
Authors
Affiliations
Background: Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size.
Setting: We retrospectively investigated factors associated with HIV-1 DNA levels in European, perinatally HIV-infected children starting antiretroviral therapy (ART) <6 months of age.
Methods: Total HIV-1 DNA was measured from 51 long-term suppressed children aged 6.3 years (median) after initial viral suppression. Factors associated with log10 total HIV-1 DNA were analyzed using linear regression.
Results: At ART initiation, children were aged median [IQR] 2.3 [1.2-4.1] months, CD4% 37 [24-45] %, CD8% 28 [18-36] %, log10 plasma viral load (VL) 5.4 [4.4-5.9] copies per milliliter. Time to viral suppression was 7.98 [4.6-19.3] months. After suppression, 13 (25%) children had suboptimal response [≥2 consecutive VL 50-400 followed by VL <50] and/or experienced periods of virological failure [≥2 consecutive VL ≥400 followed by VL <50]. Median total HIV-1 DNA was 43 [6195] copies/10 PBMC. Younger age at therapy initiation was associated with lower total HIV-1 DNA (adjusted coefficient [AC] 0.12 per month older, P = 0.0091), with a month increase in age at ART start being associated with a 13% increase in HIV DNA. Similarly, a higher proportion of time spent virally suppressed (AC 0.10 per 10% higher, P = 0.0022) and the absence of viral failure/suboptimal response (AC 0.34 for those with fail/suboptimal response, P = 0.0483) were associated with lower total HIV-1 DNA.
Conclusions: Early ART initiation and a higher proportion of time suppressed are linked with lower total HIV-1 DNA. Early ART start and improving adherence in perinatally HIV-1-infected children minimize the size of viral reservoir.
Kosmider E, Wallner J, Gervassi A, Bender Ignacio R, Pinto-Santini D, Gornalusse G PLoS One. 2024; 19(7):e0288895.
PMID: 38976697 PMC: 11230552. DOI: 10.1371/journal.pone.0288895.
Gartner K, Dominguez-Rodriguez S, Heaney J, Gkouleli T, Grant P, Dorgham K Front Immunol. 2024; 15:1334236.
PMID: 38444847 PMC: 10912947. DOI: 10.3389/fimmu.2024.1334236.
Bekka S, Kelly K, Haaren M, Dhummakupt A, Persaud D Curr Opin HIV AIDS. 2024; 19(2):79-86.
PMID: 38169427 PMC: 11715321. DOI: 10.1097/COH.0000000000000839.
Nguyen A, Plotkin A, Odumade O, de Armas L, Pahwa S, Morrocchi E Pediatr Res. 2023; 94(5):1667-1674.
PMID: 37308683 DOI: 10.1038/s41390-023-02669-0.
Mageda K, Kulemba K, Olomi W, Kapologwe N, Katalambula L, Petrucka P AIDS Res Ther. 2023; 20(1):22.
PMID: 37055786 PMC: 10099818. DOI: 10.1186/s12981-023-00515-1.